Rain oncology stock.

May 22, 2023. NEWARK, Calif., May 22, 2023 – Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and ... Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K Advanced Charting...Oct 20, 2023 · Get Rain Oncology Inc (RAIN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Shares of Rain Oncology ( RAIN 0.96%) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated ...

News Rain Oncology Inc. No significant news for in the past two years. Shares Sold Short. 613,765. Change from Last. 38.59%. Percent of Float. 3.02%.

When it rains, most flies hide in any small sheltered spot where they are protected and out of the rain. Some tiny or very large types of flies may continue to fly. According to The Straight Dope, flies shelter under leaves, in crevices or ...Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative antibody-based products under investigation using a range of cutting-edge technologies, licensed from one of the largest and most prestigious cancer-care …

4 Wall Street analysts have issued 1 year target prices for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 629.2% from the stock's current price.Rain Oncology is a clinical-stage company researching, developing and translating innovative targeted therapies for patients with cancer to help provide them hope to get their lives back. Our ...Web‍ Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic ...Nov 22, 2023 · What is Rain Oncology's stock price target for 2024? 12 Wall Street research analysts have issued twelve-month price objectives for Rain Oncology's shares. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. Cardiff Oncology stock price target cut to $14 from $25 at Maxim Group. Jan. 24, 2022 at 7:47 a.m. ET by Tomi Kilgore. Cardiff Oncology stock price target raised to $25 from $20 at Maxim Group.

May 30, 2023 · Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit.

With Rain Oncology stock trading at $1.07 per share, the total value of Rain Oncology stock (market capitalization) is $38.92M.Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an …Web

Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ...WebRain Therapeutics Inc. (RAIN) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Add to watchlist 2W 10W 9M 5.76 +0.01 (+0.17%) At close: 04:00PM EST 5.93 +0.17 (+2.95%) After hours: 04:38PM... 31 Jan 2023 ... Roth Capital Partners renewed coverage of Rain Oncology (Rain Oncology Stock Quote, Charts, News, Analysts, Financials NASDAQ:RAIN) on ...Both women are smiling. oncologist stock pictures, royalty-free photos & images. Female doctor consults patient with cancer. An female doctor is meeting with a mature adult patient fighting cancer. The patient is a Chinese woman. She is wearing a bandana to hide her hair loss from chemotherapy treatment.1,000+ best royalty free rain videos & rainfall stock video clips & footage. Download high-quality HD & 4K rain videos on desktop or mobile for your next project. Royalty-free videos. waterfall water river. 4K 00:20. rain water window wet. HD 00:33. rain thunder water. SD 00:36. rainy rain night. HD 01:01. storm ocean sky rain. HD 00:40. rain ...

Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at …WebJan 20, 2023 · PURPOSE This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. PATIENTS AND METHODS In this first-in-human phase I study, patients with advanced solid tumors or lymphomas received milademetan orally once daily as extended/continuous (days 1-21 or 1 ... Elevation Oncology stock price target cut to $21 from $27 at Wedbush. Mar. 4, 2022 at 7:28 a.m. ET by Tomi Kilgore.May 11, 2023 · NEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ... On average, Wall Street analysts predict that Rain Oncology's share price could fall to $1.00 by Sep 18, 2024. The average Rain Oncology stock price prediction ...We would like to show you a description here but the site won’t allow us.Image text: With a per-share price of less than $20, Exelixis is one of the most affordable cancer biotech stocks on our list. 5. Kura Oncology. Another of the most affordable cancer stocks to buy, Kura Oncology NASDAQ: KURA is a clinical-stage biopharmaceutical company focused entirely on cancer research.

View the latest Oncology Pharma Inc. (ONPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.Description. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology.Web

Nov 27, 2023 · Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating. NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of ...31 May 2023 ... Rain plans to continue evaluating the Phase 3 MANTRA data and present those findings at a medical conference later in the year. The company also ...1 Jun 2021 ... Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish ...Get the latest Oncology Pharma Inc (ONPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.

Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at …Web

Fourth Quarter and Full Year 2022 Financial Results. For the three months and year ended December 31, 2022, Rain reported a net loss of $22.7 million and $75.7 million, respectively, as compared ...

Coming off stock drops following safety concerns over its recently approved eye injection Syfovre--which turned out to be related to the needle used to deliver the medicine, ... Rain Oncology is laying off 65% of its staff, including its chief medical officer. This news came one week after the company's lead candidate, ...Which Rain Oncology insiders have been selling company stock? The following insider sold RAIN shares in the last 24 months: Boxer Capital, Llc ($1,243,750.00). How much insider selling is happening at Rain Oncology?Rain Oncology Inc Stock Price History. Rain Oncology Inc’s price is currently up 19.56% so far this month. During the month of January, Rain Oncology Inc’s stock price has reached a high of $14.48 and a low of $7.60. For the year, Rain Oncology Inc has hit prices as high as $14.48 and as low as $2.15. Year to date, Rain Oncology Inc’s ...The stock has increased 17.9% in price over the past month and closed Friday's trading session at $3.03. Each of the four Wall Street analysts that rated ELEV rated it Buy. The 12-month median ...Get the latest Rain Oncology Inc. (RAIN) stock news and headlines to help you in your trading and investing decisions. NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to ...WebNov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebUS75082Q1058. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. Show more.Web

With Rain Oncology stock trading at $1.07 per share, the total value of Rain Oncology stock (market capitalization) is $38.92M.Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an …WebOct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ...NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology Inc. effective ...Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, …Instagram:https://instagram. etrade how to buy stockgnln stock forecastzim stock next dividend dateinvest in uranium Rain Therapeutics Inc. (RAIN) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Add to watchlist 2W 10W 9M 5.76 +0.01 (+0.17%) At close: 04:00PM EST 5.93 +0.17 (+2.95%) After hours: 04:38PM...Nov 4, 2022 · Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per ... fidelity stock pricesforex trading best broker Rain Oncology. stock last closed at $1.11, up 5.71% from the previous day, and has decreased 86.09% in one year. It has underperformed other stocks in the Biotechnology industry by 0.59 percentage points. Rain Oncology stock is currently +35.37% from its 52-week low of $0.82, and -92.33% from its 52-week high of $14.48. schx etf Rain Oncology stock plummets on late-stage cancer drug results - San Francisco Business Times bizjournals.com 1 Like Comment Share Copy; LinkedIn; Facebook; Twitter; To view ...Rain Oncology. stock last closed at $1.11, up 5.71% from the previous day, and has decreased 86.09% in one year. It has underperformed other stocks in the Biotechnology industry by 0.59 percentage points. Rain Oncology stock is currently +35.37% from its 52-week low of $0.82, and -92.33% from its 52-week high of $14.48.At …Web